More than 15 years of collaboration, over €150 million invested in research, and 11 successful international funding calls have positioned TRANSCAN as one of Europe's most established networks supporting translational cancer research. This week, the programme entered a new phase with the official launch of TRANSCAN-4.
On 11 and 12 June, representatives from 30 partner organisations across 17 countries gathered at the Champalimaud Foundation in Lisbon, Portugal, for the TRANSCAN-4 Kick-off Meeting. The event brought together project partners, governance bodies and representatives of the European Commission to define the roadmap for the coming years and reinforce a shared commitment to improving outcomes for cancer patients through research and innovation.
TRANSCAN-4 aims to accelerate the translation of scientific discoveries into clinical practice by fostering international collaboration and supporting high-impact research projects that address key challenges in cancer prevention, diagnosis and treatment.
The first day of the meeting focused on strategic planning and programme implementation. Partners reviewed the objectives of the new phase and discussed priorities for future activities, including the launch of new funding opportunities and initiatives designed to strengthen collaboration across Europe.
A major milestone highlighted during the meeting was the opening of the first TRANSCAN-4 Joint Transnational Call (JTC 2026), which will support multinational research projects under the topic "Translational Research on Cancer Metabolism: Multidisciplinary Approaches for Diagnosis and Treatment."
The second day brought together members of the Scientific Advisory Board and the Network Steering Committee to discuss future funding priorities, evaluate emerging scientific challenges and ensure that research investments remain aligned with the needs of patients and society. Discussions also focused on strengthening cooperation among participating countries and maximising the impact of funded projects.
Building on a strong legacy of collaboration, TRANSCAN-4 continues its mission to advance translational cancer research across Europe and beyond. The Lisbon meeting marked the beginning of a new phase of joint efforts aimed at transforming scientific knowledge into tangible benefits for patients.
As the kick-off meeting concluded, partners reaffirmed their commitment to long-term cooperation, scientific excellence and the continued development of innovative solutions to address cancer-related challenges. The work of TRANSCAN-4 has now officially begun.